Biography

Miraz Rahman is a Professor of Medicinal Chemistry in School of Cancer & Pharmaceutical Sciences, King’s College London. After working three years in the industry, he went back to academia and obtained his PhD from the School of Pharmacy (currently UCL School of Pharmacy) in synthetic medicinal chemistry. His research activities are focused on the application of advanced computational chemistry, synthetic medicinal chemistry and chemical biology techniques to the design, synthesis and evaluation of novel drug-like chemical scaffolds as anticancer and anti-infective agents. He joined King’s College London in 2012 and currently holds the position of Chair in Medicinal Chemistry and Antimicrobial Research Theme Lead of Institute of Pharmaceutical Science. He is working with UK Health Security Agency to develop new generation efflux resistant antimicrobials and new chemical tools to study antimicrobial resistance (AMR). His research group has invented new classes of efflux resistant antibiotics and antifungal agents that are currently being commercialised. Professor Rahman has experience in both early and late-stage drug discovery and translational research, co-founding Transcriptogen Ltd (2013), Femtogenix Ltd (2015) and the antibiotic company Necobiotix Ltd (2020).